Clinical trials: Group 2 Pulmonary Hypertension
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Pharmacogenomics in Pulmonary Arterial Hypertension
Our goal is to determine clinically in Pulmonary Arterial Hypertension patients if associations exist between the efficacy and toxicity of sitaxsentan, bosentan, and ambrisentan and several gene polymorphisms in several key…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
- Trial name
- NCT00593905
- Testing
- Sitaxsentan, Bosentan, Ambrisentan
- Where
- United States
- Sponsor
- West Penn Allegheny Health System
Pulmonary Hypertension Group 1 and 4 According to Nice Classification
NIMS- New Implantable Pump in Pulmonary Arterial Hypertension, a Safety Follow up
This observational study aims to chart patients which get their prostacyclin treatment via the subcutaneous LenusPro pump. How the surgical procedure is performed and the clinical follow-up of these patients.
- Trial name
- NCT01977014
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 40 people
- Sponsor
- NordicInfu Care AB